MYC and inflammatory breast carcinoma: Using NGS, inflammatory breast cancer (IBC) exhibited clinically significant genetic alterations (CRGA) in genes like TP53, MYC, ERBB2, FGFR1, BRCA2, and PTEN. This information guides personalized treatment, transitioning from traditional chemotherapy to more targeted therapies, potentially enhancing efficacy and minimizing side effects [65].